

Karen Leroy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4492272/publications.pdf>

Version: 2024-02-01

114
papers

7,605
citations

53794

45
h-index

53230

85
g-index

118
all docs

118
docs citations

118
times ranked

10137
citing authors

#	ARTICLE	IF	CITATIONS
1	The alternative RelB NF- κ B subunit is a novel critical player in diffuse large B-cell lymphoma. <i>Blood</i> , 2022, 139, 384-398.	1.4	29
2	Redifferentiating Effect of Larotrectinib in <i>NTRK</i> -Rearranged Advanced Radioactive-Iodine Refractory Thyroid Cancer. <i>Thyroid</i> , 2022, 32, 594-598.	4.5	19
3	Transcriptome in paraffin samples for the diagnosis and prognosis of adrenocortical carcinoma. <i>European Journal of Endocrinology</i> , 2022, 186, 607-617.	3.7	2
4	Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors. <i>European Journal of Cancer</i> , 2022, 166, 87-99.	2.8	21
5	Discovery and validation of a transcriptional signature identifying homologous recombination-deficient breast, endometrial and ovarian cancers. <i>British Journal of Cancer</i> , 2022, 127, 1123-1132.	6.4	3
6	c-Rel Is the Pivotal NF- κ B Subunit in Germinal Center Diffuse Large B-Cell Lymphoma: A LYSA Study. <i>Frontiers in Oncology</i> , 2021, 11, 638897.	2.8	7
7	EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy. <i>Cancers</i> , 2021, 13, 5132.	3.7	9
8	Standardisation of pathogenicity classification for somatic alterations in solid tumours and haematologic malignancies. <i>European Journal of Cancer</i> , 2021, 159, 1-15.	2.8	7
9	Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study. <i>Cancers</i> , 2020, 12, 473.	3.7	72
10	Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma. <i>Journal of Thoracic Oncology</i> , 2020, 15, 860-866.	1.1	84
11	The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort. <i>Journal of Translational Medicine</i> , 2019, 17, 357.	4.4	88
12	Isolated 5 α - β Signals Are an Atypical Pattern To Be Considered as Positive for ALK Rearrangement: A Brief Report of Three Cases and Review of the Literature. <i>Translational Oncology</i> , 2019, 12, 784-787.	3.7	5
13	The NRF2 transcriptional target NQO1 has low mRNA levels in TP53-mutated endometrial carcinomas. <i>PLoS ONE</i> , 2019, 14, e0214416.	2.5	10
14	Dimethyl fumarate, a two-edged drug: Current status and future directions. <i>Medicinal Research Reviews</i> , 2019, 39, 1923-1952.	10.5	98
15	Refining diffuse large B-cell lymphoma subgroups using integrated analysis of molecular profiles. <i>EBioMedicine</i> , 2019, 48, 58-69.	6.1	29
16	Somatic IL4R mutations in primary mediastinal large B-cell lymphoma lead to constitutive JAK-STAT signaling activation. <i>Blood</i> , 2018, 131, 2036-2046.	1.4	39
17	STAT6 is a cargo of exportin 1: Biological relevance in primary mediastinal B-cell lymphoma. <i>Cellular Signalling</i> , 2018, 46, 76-82.	3.6	15
18	Authors' Reply. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 266.	2.8	0

#	ARTICLE	IF	CITATIONS
19	Dimethyl fumarate is highly cytotoxic in KRAS mutated cancer cells but spares non-tumorigenic cells. <i>Oncotarget</i> , 2018, 9, 9088-9099.	1.8	29
20	Dimethyl Fumarate Controls the NRF2/DJ-1 Axis in Cancer Cells: Therapeutic Applications. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 529-539.	4.1	54
21	Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients. <i>Investigational New Drugs</i> , 2017, 35, 436-441.	2.6	73
22	BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial. <i>Annals of Oncology</i> , 2017, 28, 1042-1049.	1.2	21
23	Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases. <i>Clinical Cancer Research</i> , 2017, 23, 2232-2244.	7.0	82
24	Determination of Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Reverse Transcriptase Multiplex Ligation-Dependent Probe Amplification Classifier. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 892-904.	2.8	39
25	DNA degrades during storage in formalin-fixed and paraffin-embedded tissue blocks. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 491-500.	2.8	80
26	Reliable subtype classification of diffuse large B-cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay. <i>Haematologica</i> , 2017, 102, e404-e406.	3.5	16
27	Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 251-267.	2.8	75
28	Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 923-930.	4.1	79
29	Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts). <i>Annals of Oncology</i> , 2016, 27, vi29.	1.2	0
30	Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment. <i>Annals of Oncology</i> , 2016, 27, 1311-1316.	1.2	49
31	Identification of patients at risk for severe toxicity under PD1 inhibitors: role of sarcopenic overweight. <i>Annals of Oncology</i> , 2016, 27, vi373.	1.2	0
32	Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study. <i>Clinical Cancer Research</i> , 2016, 22, 2919-2928.	7.0	181
33	Three Rounds of External Quality Assessment in France to Evaluate the Performance of 28 Platforms for Multiparametric Molecular Testing in Metastatic Colorectal and Non-Small Cell Lung Cancer. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 205-214.	2.8	23
34	Classification of diffuse large b-cell lymphoma (DLBCL) FFPE samples of the GELA LNH2003 program, using Lymph2Cx assay on the nCounter analysis system.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7547-7547.	1.6	0
35	A multidisciplinary team dedicated to the management of patients treated with PD1 inhibitors: The Cochin hospital experience.. <i>Journal of Clinical Oncology</i> , 2016, 34, e18208-e18208.	1.6	0
36	Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and Non-L265P Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases. <i>Blood</i> , 2016, 128, 4097-4097.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Integrated Analysis of IGHV Gene Status, Cell-of-Origin Signature and Genomic Features in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 4118-4118.	1.4	0
38	BRAF V600E mutations in bile duct adenomas. <i>Hepatology</i> , 2015, 61, 403-405.	7.3	19
39	MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study. <i>Blood</i> , 2015, 126, 2466-2474.	1.4	212
40	Somatic mutations of cell-free circulating DNA detected by next-generation sequencing reflect the genetic changes in both germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphomas at the time of diagnosis. <i>Haematologica</i> , 2015, 100, e280-e284.	3.5	69
41	Accurate Classification of Germinal Center B-Cell-Like/Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Using a Simple and Rapid Reverse Transcriptase-Multiplex Ligation-Dependent Probe Amplification Assay. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 273-283.	2.8	50
42	Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial - the PRODIGE 22 - ECKINOXE trial. <i>BMC Cancer</i> , 2015, 15, 511.	2.6	43
43	Recurrent Mutations of the Exportin 1 Gene (XPO1) in Primary Mediastinal B-Cell Lymphoma: A Lysa Study. <i>Blood</i> , 2015, 126, 129-129.	1.4	2
44	Abstract 4810: Exome sequencing of refractory diffuse large B-cell lymphomas highlights candidate genes for targeted resequencing. , 2015, , .		0
45	Integrative Analysis of Diffuse Large B Cell Lymphoma Mutational Landscape: A Lysa Study. <i>Blood</i> , 2015, 126, 1472-1472.	1.4	0
46	Young Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma Benefit From Intensified Chemotherapy With ACVBP Plus Rituximab Compared With CHOP Plus Rituximab: Analysis of Data From the Groupe d'Etudes des Lymphomes de l'Adulte/Lymphoma Study Association Phase III Trial LNH 03-2B. <i>Journal of Clinical Oncology</i> , 2014, 32, 3996-4003.	1.6	79
47	Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy. <i>Clinical Cancer Research</i> , 2014, 20, 3338-3347.	7.0	98
48	Rituximab, alkylating agents or combination therapy for gastric mucosa-associated lymphoid tissue lymphoma: a monocentric non-randomised observational study. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 619-628.	3.7	19
49	The Activation of the WNT Signaling Pathway Is a Hallmark in Neurofibromatosis Type 1 Tumorigenesis. <i>Clinical Cancer Research</i> , 2014, 20, 358-371.	7.0	44
50	Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma. <i>Nature Genetics</i> , 2014, 46, 329-335.	21.4	180
51	DNA comparison between operative and biopsy specimens to investigate stage pT0 after radical prostatectomy. <i>World Journal of Urology</i> , 2014, 32, 899-904.	2.2	2
52	Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. <i>Blood</i> , 2014, 124, 3016-3019.	1.4	197
53	Targeting STAT6 in PMBL. <i>Oncotarget</i> , 2014, 5, 7216-7216.	1.8	3
54	MicroRNAome profiling in benign and malignant neurofibromatosis type 1-associated nerve sheath tumors: evidences of PTEN pathway alterations in early NF1 tumorigenesis. <i>BMC Genomics</i> , 2013, 14, 473.	2.8	46

#	ARTICLE	IF	CITATIONS
55	Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group. BMC Cancer, 2013, 13, 472.	2.6	11
56	Immunoglobulin heavy chain/light chain pair measurement is associated with survival in diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2013, 54, 1898-1907.	1.3	36
57	Rituximab and chlorambucil versus rituximab alone in gastric mucosa-associated lymphoid tissue lymphoma according to t(11;18) status: a monocentric non-randomized observational study. Leukemia and Lymphoma, 2013, 54, 940-944.	1.3	29
58	ER stress in diffuse large B cell lymphoma: GRP94 is a possible biomarker in germinal center versus activated B-cell type. Leukemia Research, 2013, 37, 3-8.	0.8	6
59	Performance and Cost Efficiency of KRAS Mutation Testing for Metastatic Colorectal Cancer in Routine Diagnosis: The MOKAECM Study, a Nationwide Experience. PLoS ONE, 2013, 8, e68945.	2.5	23
60	Accurate Classification Of GCB/ABC and MYC/BCL2 Diffuse Large B-Cell Lymphoma With a 14 Genes Expression Signature and a Simple and Robust RT-MLPA Assay. Blood, 2013, 122, 84-84.	1.4	3
61	STAT6-mediated BCL6 repression in primary mediastinal B-cell lymphoma (PMBL). Oncotarget, 2013, 4, 1093-1102.	1.8	32
62	Protein Tyrosine Phosphatase Type-1 (PTPN1) Is Frequently Mutated In Primary Mediastinal B Cell Lymphoma and Hodgkin Lymphoma. Blood, 2013, 122, 242-242.	1.4	1
63	Is Elevated Gastric Tissue NOX2 Associated with Lymphoma of Mucosa-Associated Lymphoid Tissue?. Antioxidants and Redox Signaling, 2012, 16, 1205-1211.	5.4	7
64	A Meta-Analysis of the Relationship between FGFR3 and TP53 Mutations in Bladder Cancer. PLoS ONE, 2012, 7, e48993.	2.5	47
65	<i>CDKN2A</i> homozygous deletion is associated with muscle invasion in <i>FGFR3</i> mutated urothelial bladder carcinoma. Journal of Pathology, 2012, 227, 315-324.	4.5	90
66	Expression of MYC, IgM, As Well As Non-Germinal Centre B-Cell Like Immunophenotype and Positive Immunofish Index Predict a Worse Progression Free Survival and Overall Survival in a Series of 670 De Novo Diffuse Large B-Cell Lymphomas Included in Clinical Trials: A GELA Study of the 2003 Program. Blood, 2012, 120, 1539-1539.	1.4	1
67	Integrated Analysis of High-Resolution Gene Expression and Copy Number Profiling Identified Biallelic Deletion of CDKN2A/2B Tumor Suppressor Locus As the Most Frequent and Unique Genomic Abnormality in Diffuse Large B-Cell Lymphoma (DLBCL) with Strong Prognostic Value in Both GCB and ABC Subtypes and Not Overcome by a Dose-Intensive Immunochemotherapy Regimen Plus Rituximab. Results of a Prospective GELA Clinical Trial Program. Blood, 2012, 120, 415-415.	1.4	6
68	BCL2 Negative Follicular Lymphoma with BCL6 Gene Rearrangement Show Mutations of STAT6 DNA Binding Domain. Blood, 2012, 120, 1559-1559.	1.4	0
69	SOX9 expression increases with malignant potential in tumors from patients with neurofibromatosis 1 and is not correlated to desert hedgehog. Human Pathology, 2011, 42, 434-443.	2.0	10
70	Identification of Genes Potentially Involved in the Increased Risk of Malignancy in NF1-Microdeleted Patients. Molecular Medicine, 2011, 17, 79-87.	4.4	46
71	Role of Noncoding RNA ANRIL in Genesis of Plexiform Neurofibromas in Neurofibromatosis Type 1. Journal of the National Cancer Institute, 2011, 103, 1713-1722.	6.3	106
72	R-ACVBP Benefits to Younger Patients with Non-Germinal Centre Diffuse Large B-Cell Lymphoma As Compared to R-CHOP in the GELA Trial LNH03-2B. Blood, 2011, 118, 2632-2632.	1.4	5

#	ARTICLE	IF	CITATIONS
73	Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study. <i>Blood</i> , 2010, 116, 1092-1104.	1.4	122
74	Occupational exposure to polycyclic aromatic hydrocarbons influenced neither the frequency nor the spectrum of FGFR3 mutations in bladder urothelial carcinoma. <i>Molecular Carcinogenesis</i> , 2010, 49, 25-31.	2.7	4
75	Differential Expression of <i>CCN1</i> , <i>CYR61</i> , <i>CCN3/NOV</i> , <i>CCN4/WISP1</i> , and <i>CCN5/WISP2</i> in Neurofibromatosis Type 1 Tumorigenesis. <i>Journal of Neuropathology and Experimental Neurology</i> , 2010, 69, 60-69.	1.7	16
76	Treatment of t(11;18)-positive gastric mucosa-associated lymphoid tissue lymphoma with rituximab and chlorambucil: clinical, histological, and molecular follow-up. <i>Leukemia and Lymphoma</i> , 2010, 51, 284-290.	1.3	45
77	Immunofluorescence In Situ Hybridization Index Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP: A GELA Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 5573-5579.	1.6	113
78	Evaluation of a low density DNA microarray for small B-cell non-Hodgkin lymphoma differential diagnosis. <i>Leukemia and Lymphoma</i> , 2009, 50, 410-418.	1.3	4
79	Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma. <i>Blood</i> , 2009, 114, 1236-1242.	1.4	111
80	The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. <i>Leukemia</i> , 2008, 22, 1917-1924.	7.2	95
81	STAT6 activity is regulated by SOCS-1 and modulates BCL-XL expression in primary mediastinal B-Cell lymphoma. <i>Leukemia</i> , 2008, 22, 2106-2110.	7.2	43
82	CD158K/KIR3DL2 Transcript Detection in Lesional Skin of Patients with Erythroderma Is a Tool for the Diagnosis of Sezary Syndrome. <i>Journal of Investigative Dermatology</i> , 2008, 128, 465-472.	0.7	51
83	Mucosa-associated lymphoid tissue lymphoma in patients with human immunodeficiency virus infection. <i>British Journal of Haematology</i> , 2008, 140, 470-474.	2.5	18
84	Primary Hepatic Lymphoma of Mucosa-Associated Lymphoid Tissue Type: A Case Report With Cytogenetic Study. <i>International Journal of Surgical Pathology</i> , 2008, 16, 301-307.	0.8	14
85	Involvement of the Leptin Receptor in the Immune Response in Intestinal Cancer. <i>Cancer Research</i> , 2008, 68, 9413-9422.	0.9	40
86	High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. <i>Gut</i> , 2008, 57, 772-779.	12.1	190
87	Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. <i>Blood</i> , 2008, 112, 3088-3098.	1.4	173
88	Microarray-Based Identification of Tenascin C and Tenascin XB, Genes Possibly Involved in Tumorigenesis Associated with Neurofibromatosis Type 1. <i>Clinical Cancer Research</i> , 2007, 13, 398-407.	7.0	48
89	Human IL411 is a secreted l-phenylalanine oxidase expressed by mature dendritic cells that inhibits T-lymphocyte proliferation. <i>Blood</i> , 2007, 110, 220-227.	1.4	140
90	The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. <i>Blood</i> , 2007, 109, 4952-4963.	1.4	533

#	ARTICLE	IF	CITATIONS
91	Antiproliferative Effect of Semaphorin 3F on Human Melanoma Cell Lines. <i>Journal of Investigative Dermatology</i> , 2006, 126, 2343-2345.	0.7	19
92	Protocadherin 15 (PCDH15): a new secreted isoform and a potential marker for NK/T cell lymphomas. <i>Oncogene</i> , 2006, 25, 2807-2811.	5.9	23
93	Mucosa-associated lymphoid tissue lymphoma of the thymus: a case report with no evidence of MALT1 rearrangement. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2005, 446, 189-193.	2.8	28
94	Prognostic Value of Translocation t(11;18) in Tumoral Response of Low-Grade Gastric Lymphoma of Mucosa-Associated Lymphoid Tissue Type to Oral Chemotherapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 5061-5066.	1.6	110
95	Metachronous gastric MALT lymphoma and early gastric cancer: is residual lymphoma a risk factor for the development of gastric carcinoma?. <i>Annals of Oncology</i> , 2005, 16, 1232-1236.	1.2	57
96	Molecular Profiles of Neurofibromatosis Type 1-Associated Plexiform Neurofibromas. <i>Clinical Cancer Research</i> , 2004, 10, 3763-3771.	7.0	34
97	Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR. <i>Molecular Cancer</i> , 2004, 3, 20.	19.2	85
98	Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis. <i>Blood</i> , 2004, 103, 2727-2737.	1.4	127
99	Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma. <i>Blood</i> , 2004, 104, 543-549.	1.4	183
100	Cell cycle checkpoint status in human malignant mesothelioma cell lines: response to gamma radiation. <i>British Journal of Cancer</i> , 2003, 88, 388-395.	6.4	18
101	Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma. <i>Journal of Experimental Medicine</i> , 2003, 198, 851-862.	8.5	1,002
102	Activated protein C resistance acquired through liver transplantation and associated with recurrent venous thrombosis. <i>Journal of Hepatology</i> , 2003, 38, 866-869.	3.7	10
103	Quantitative RT-PCR reveals a ubiquitous but preferentially neural expression of the KIS gene in rat and human. <i>Molecular Brain Research</i> , 2003, 114, 55-64.	2.3	24
104	Interleukin 4-induced gene 1 is activated in primary mediastinal large B-cell lymphoma. <i>Blood</i> , 2003, 101, 2756-2761.	1.4	61
105	p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas. <i>Annals of Oncology</i> , 2002, 13, 1108-1115.	1.2	84
106	MAL Expression in Lymphoid Cells: Further Evidence for MAL as a Distinct Molecular Marker of Primary Mediastinal Large B-Cell Lymphomas. <i>Modern Pathology</i> , 2002, 15, 1172-1180.	5.5	138
107	Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. <i>Gastroenterology</i> , 2002, 123, 1804-1811.	1.3	535
108	Expression of p53 protein in T- and natural killer-cell lymphomas is associated with some clinicopathologic entities but rarely related to p53 mutations. <i>Human Pathology</i> , 2001, 32, 196-204.	2.0	34

#	ARTICLE	IF	CITATIONS
109	The MAL Gene Is Expressed in Primary Mediastinal Large B-Cell Lymphoma. <i>Blood</i> , 1999, 94, 3567-3575.	1.4	119
110	Identification of a novel cDNA, encoding a cytoskeletal associated protein, differentially expressed in diffuse large B cell lymphomas. <i>Oncogene</i> , 1998, 17, 1245-1251.	5.9	38
111	Correlations between p53 overexpression, serum antibodies and gene mutation in colorectal cancer. <i>Gastroenterology</i> , 1998, 114, A605.	1.3	0
112	Human Interleukin-10 Expression in T/Natural Killer-Cell Lymphomas. <i>American Journal of Pathology</i> , 1998, 153, 1229-1237.	3.8	75
113	Erythropoietic protoporphyria in the house mouse. A recessive inherited ferrochelatase deficiency with anemia, photosensitivity, and liver disease.. <i>Journal of Clinical Investigation</i> , 1991, 88, 1730-1736.	8.2	116
114	Fate of β -Hemoglobin Chains and Erythrocyte Defects in β -Thalassemia. <i>Annals of the New York Academy of Sciences</i> , 1990, 612, 106-117.	3.8	32